Tina Bhutani, MD, MAS, FAAD, discusses new data presented at the 2026 American Academy of Dermatology annual meeting for the treatment of generalized pustular psoriasis
Leonardo Tjahjono, MD, FAAD, a clinical dermatologist at George Washington University in Washington, DC, discusses dosing regimens for spesolimab (Spevigo) every 4 weeks vs 12
Boni Elewski, MD, a professor and chair of dermatology at the University of Alabama in Birmingham, Alabama, discusses the characteristics and diagnosis of generalized pustular
Dr. Chovatiya discusses evolving treatment strategies for Generalized Pustular Psoriasis (GPP) and how recent clinical research is reshaping the management paradigm for this severe inflammatory
Dr. Johann Gudjonsson discusses how spesolimab may reduce low-grade inflammation between flares in patients with generalized pustular psoriasis (GPP). Topics Covered: Subclinical inflammation in GPP
Dr. Bhutani reviews the underlying disease mechanisms of Generalized Pustular Psoriasis (GPP), focusing on the role of inflammatory signaling pathways that drive the condition. Her
Dr. Bhutani examines the significant quality-of-life burden associated with Generalized Pustular Psoriasis (GPP), a rare and severe inflammatory skin condition. Her discussion highlights how frequent
Dr. Bhutani discusses the diagnostic challenges associated with Generalized Pustular Psoriasis (GPP), a rare and often unpredictable inflammatory skin disease. Her presentation highlights the importance
